The problems with polypharmacy
Polypharmacy, or the concomitant use of multiple medicines, is estimated to cost $18 billion and account for 8.6 million hospital admissions annually in the European Union. The iSIMPATHY […]
Polypharmacy, or the concomitant use of multiple medicines, is estimated to cost $18 billion and account for 8.6 million hospital admissions annually in the European Union. The iSIMPATHY […]
The real world evidence about ivermectin combined with the findings from meta-analyses of clinical trials provide compelling evidence for the safety and effectiveness of ivermectin, according to Dr […]
The results of the recent controlled trial of ivermectin for covid-19 in Colombia suggest that both ivermectin and control groups received ivermectin, according to Dr David Scheim. https://www.youtube.com/watch?v=T67szXgTqWw&ab_channel=MedicalUpdateOnline […]
Dr David Scheim explains how multiple protocol violations and widespread use of over-the-counter ivermectin could have compromised the results of a recent controlled trial of ivermectin for covid-19 […]
Dr David Scheim explains how the original analysis factored out confounders and showed a 74% reduction in deaths at 30 days as a result of intensive ivermectin distribution. […]
Further analysis of results from Peru has now shown that systematic treatment of the population for covid-19 with ivermectin resulted in a 14-fold reduction in excess deaths. IMI interviewed Dr […]
Ivermectin is a good treatment to use interim to and complementary to immunisations, according to Dr David Scheim, one of the authors of a study of mass treatment for covid-19 […]
Dr David Scheim, one of the authors of a recent study in Peru, describes the doses of ivermectin that were used and the strategies for effective mass distribution. https://www.youtube.com/watch?v=MSkKU18VlNo […]
Mature, real world data on systematic mass treatment of covid-19 with ivermectin show a sharp fall in excess deaths. IMI interviewed Dr David Scheim, one of the authors […]
Delayed diagnoses and more patients with advanced cancers were consequences of the coronavirus pandemic, according to Dr Erin Schenk, Assistant Professor, Thoracic Oncology, University of Colorado. The coronavirus […]
Modern lung cancer treatment has changed the outlook for lung cancer patients considerably and interesting trial results are expected this year, according to Dr Erin Schenk, Assistant Professor, […]
Dr Erin Schenk, Assistant Professor, Thoracic Oncology, University of Colorado describes the results of the ADAURA trial and the implications for her practice. The other trial that has […]